After more than two years ramping up supplies of existing medicines used to treat COVID-19, interest in developing products for the pandemic may be winding down for the brand and generic industries alike.
US Food and Drug Administration data suggests that COVID-19-related generic approvals have mostly declined since peaking during the October-December 2020...







